Menu Search
Equities

Chugai Pharmaceutical Co Ltd

4519:TYO

Chugai Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)6,383.00
  • Today's Change-1.00 / -0.02%
  • Shares traded1.63m
  • 1 Year change+31.99%
  • Beta0.8694
Data delayed at least 20 minutes, as of Nov 21 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform5
Hold7
Sell0
Strong Sell0

Share price forecast in JPY

The 12 analysts offering 12 month price targets for Chugai Pharmaceutical Co Ltd have a median target of 7,800.00, with a high estimate of 9,900.00 and a low estimate of 4,500.00. The median estimate represents a 22.20% increase from the last price of 6,383.00.
High55.1%9,900.00
Med22.2%7,800.00
Low-29.5%4,500.00

Dividends in JPY

In 2023, Chugai Pharmaceutical Co Ltd reported a dividend of 80.00 JPY, which represents a 2.56% increase over last year. The 11 analysts covering the company expect dividends of 89.00 JPY for the upcoming fiscal year, an increase of 11.25%.
Div growth (TTM)2.56%
More ▼

Earnings history & estimates in JPY

On Oct 25, 2024, Chugai Pharmaceutical Co Ltd reported 3rd quarter 2024 earnings of 66.55 per share. This result exceeded the 61.50 consensus of the 4 analysts covering the company and exceeded last year's 3rd quarter results by 41.15%.
The next earnings announcement is expected on Jan 30, 2025.
Average growth rate+11.84%
Chugai Pharmaceutical Co Ltd reported annual 2023 earnings of 197.83 per share on Feb 01, 2024.
Average growth rate+21.91%
More ▼

Revenue history & estimates in JPY

Chugai Pharmaceutical Co., Ltd. had 3rd quarter 2024 revenues of 315.68m. This bettered the 276.20m consensus of the 6 analysts covering the company. This was 1.10% above the prior year's 3rd quarter results.
Average growth rate+6.49%
Chugai Pharmaceutical Co., Ltd. had revenues for the full year 2023 of 1.11bn. This was 11.79% below the prior year's results.
Average growth rate+13.99%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.